Focus Wealth Management initiated a position in Abbott Laboratories during the second quarter of 2026, according to its Q2 2026 investor letter. The fund described Abbott as a diversified healthcare company with leading franchises across medical devices, diagnostics and nutrition, and said recent operational challenges that weighed on the share price appear temporary rather than structural. Abbott has raised its dividend for more than 50 consecutive years and continues to invest heavily in innovation, which the firm said offers an attractive combination of quality, resilience and valuation. Abbott closed at $103.69 per share on September 22, 2026, down 9.12% over the past month and 22.56% over the past 52 weeks, with a market capitalization of $179.42 billion and a 52-week range of $81.97 to $136.83. The fund also said it continues to see selective opportunities in U.S. health care, a sector that has largely sat outside the center of market enthusiasm.
Abbott LaboratoriesFocus Wealth Management initiated a new position in Abbott, calling its recent operational challenges temporary and citing quality, resilience and attractive valuation.
